Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KHK | P50053 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376616 | 0.84 | LMNA (0.44) | HPGDKMT2ASMN1; SMN2KHKLMNA | |
| SCHEMBL376318 | 0.83 | SLC6A4 (0.39) | HPGDKMT2ASMN1; SMN2LMNA | |
| SCHEMBL376739 | 0.83 | KMT2A (0.39) | HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL376343 | 0.83 | ALDH1A1 (0.41) | HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL1574471 | 0.80 | TACR1 (0.44) | KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL3251338 | 0.78 | TACR1 (0.43) | KMT2ASIGMAR1 | |
| SCHEMBL27326609 | 0.77 | KMT2A (0.47) | HPGDKMT2ASMN1; SMN2HRH3SIGMAR1 | |
| SCHEMBL4818025 | 0.76 | STS (0.47) | SMN1; SMN2HRH3KDM4E | |
| SCHEMBL13681482 | 0.75 | ACHE (0.42) | KDM4ELMNA | |
| SCHEMBL381716 | 0.73 | MAPT (0.49) | KMT2AHRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1487811-B1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1765778-A2 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7030115-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2005117543-A2 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1487811-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003080586-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | BAX, BCL2, BAD | HPGD 2339/4885KMT2A 3213/4885SMN1; SMN2 328/4885 |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, BAD | HPGD 2339/4885KMT2A 3213/4885SMN1; SMN2 328/4885 |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | HPGD 2179/4885KMT2A 1794/4885SMN1; SMN2 808/4885 |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, AIFM1 | HPGD 2811/4885KMT2A 3304/4885SMN1; SMN2 344/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | HPGD 2179/4885KMT2A 1794/4885SMN1; SMN2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.